Biotech; Mad Or Bad?
Glenn Dyer
August 17, 2007
9:52 am
AVX – CSL
Recent Posts
- Euro Zone Eyes a Stronger Global RoleFebruary 7, 2026
- FTSE 100 Climbs Amid Tech Sector WobblesFebruary 7, 2026
- SpaceX's xAI Acquisition Avoids Debt, TaxesFebruary 6, 2026
- US Farm Income Predicted to FallFebruary 6, 2026
- Toyota CEO Sato to Step DownFebruary 6, 2026
All Categories
- Battery Technology (2)
- Biotechnology (101)
- brekkie wrap (288)
- Broker News (2466)
- Commodities (1680)
- Hydrogen (6)
- Lithium (106)
- Potash (11)
- Rare Earths (6)
- Renewables (35)
- Company (7)
- Corporate Connect Research (24)
- Currencies (42)
- Cryptocurrencies (28)
- daily special (68)
- David Bassanese (90)
- Economics (3084)
- ESG (117)
- Etfs (500)
- EV Space (128)
- Featured (136)
- FinTech (26)
- Fixed Interest (231)
- FNN Content (6112)
- Franklin Templeton (1)
- fresh grind (2559)
- fundie guide (22)
- Funds (1422)
- Gavin Wendt (141)
- Greg Tolpigin (75)
- hot stocks (250)
- Infrastructure (28)
- Interest Rates (386)
- investor blend (65)
- IPOs (20)
- James Dunn (185)
- Kris Walesby (67)
- LICs (162)
- Marc Sinatra (4)
- market mocha (5330)
- Market Reports Text (283)
- Markets (14003)
- Media (71)
- Noosa Mining Conference (29)
- Podcasts (1)
- Politics (53)
- Product Profiles (23)
- Property (225)
- Reports (511)
- Retail (254)
- round table (8)
- Shane Oliver (260)
- Shares (18215)
- Stocks of the Hour (300)
- sip & learn (23)
- sip and learn (55)
- Sponsored Content (32)
- Strategy (204)
- Super (36)
- table for two (84)
- Technical Analysis (5)
- Technology (419)
- The Week that Was (112)
- Tim Boreham (85)
- Uncategorized (157)
- Video (4332)
- Webinars (195)
- Weekly Wrap (831)